Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Biologics Engineering, Oncology R&D, AstraZeneca, Cambridge, UK.
Nat Commun. 2023 Nov 27;14(1):7753. doi: 10.1038/s41467-023-43484-9.
Chemical inducer of dimerization (CID) modules can be used effectively as molecular switches to control biological processes, and thus there is significant interest within the synthetic biology community in identifying novel CID systems. To date, CID modules have been used primarily in engineering cells for in vitro applications. To broaden their utility to the clinical setting, including the potential to control cell and gene therapies, the identification of novel CID modules should consider factors such as the safety and pharmacokinetic profile of the small molecule inducer, and the orthogonality and immunogenicity of the protein components. Here we describe a CID module based on the orally available, approved, small molecule simeprevir and its target, the NS3/4A protease from hepatitis C virus. We demonstrate the utility of this CID module as a molecular switch to control biological processes such as gene expression and apoptosis in vitro, and show that the CID system can be used to rapidly induce apoptosis in tumor cells in a xenograft mouse model, leading to complete tumor regression.
化学诱导二聚体(CID)模块可有效用作分子开关来控制生物过程,因此,合成生物学领域内人们对鉴定新型 CID 系统有着浓厚的兴趣。迄今为止,CID 模块主要用于体外工程细胞。为了将其用途扩展到临床环境,包括控制细胞和基因疗法的潜力,新型 CID 模块的鉴定应考虑小分子诱导剂的安全性和药代动力学特征,以及蛋白成分的正交性和免疫原性。在此,我们描述了一个基于可口服、已批准的小分子simeprevir 及其靶标丙型肝炎病毒 NS3/4A 蛋白酶的 CID 模块。我们证明了该 CID 模块作为分子开关在体外控制基因表达和细胞凋亡等生物过程的用途,并表明 CID 系统可用于在异种移植小鼠模型中快速诱导肿瘤细胞凋亡,从而导致完全肿瘤消退。